How Expert Medical Writing Accelerates Your Path to First-in-Human Trials
Bringing a new therapy from discovery to first-in-human studies is one of the most exciting milestones in drug development, but also one of the most demanding.
An Investigational New Drug (IND) application is the gateway to clinical trials in the United States, and the quality of your documentation can determine whether your program advances smoothly or encounters costly delays.
Download our guide to gain the key components of a successful IND submission preparation and how expert support can streamline your path to the clinic.
IND to IMPD Adaptation to Open Sites in Europe
Morula Health supported a repeat US biotech client with medical writing for an FDA Type B meeting. By delivering clear, submission‑ready documentation, our team helped the client engage regulators with confidence and maintain program momentum.
Find out more
Redefining Therapeutic Potential: Large Oncology IND Submission
Morula Health supported a UK biotech with the delivery and management of a large oncology IND submission. Our regulatory medical writing expertise ensured consistency across complex documentation and supported a successful regulatory outcome.
Find out more
Breaking Barriers: Facilitating FDA Approval
Morula Health developed a first‑in‑human Phase 1 protocol for an FDA IND submission within five weeks. By combining regulatory insight with immuno‑oncology expertise, our team helped the client meet critical timelines and advance their program toward approval.
Find out more